CCM
VYNE icon

CAAS Capital Management’s VYNE Therapeutics VYNE Stock Holding History

CAAS Capital Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-16,465
Closed -$2.05M – 618
2020
Q2 		$2.05M Buy
+16,465
New +$2.23M 0.07% 207

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

CAAS Capital Management's VYNE Position: Q3 2020 in Review

CAAS Capital Management sold out of VYNE Therapeutics (VYNE) in Q3 2020, closing a stake of 16,465 shares — an estimated $2.05M sold.

CAAS Capital Management first reported a position in VYNE in Q2 2020 and held it in 1 quarter. The position peaked at $2.05M in Q2 2020. 105 funds tracked by Wall St. Rank hold VYNE as of Q3 2020.

  • CAAS Capital Management reported no remaining VYNE Therapeutics position as of Q3 2020 after selling out during the quarter.
  • CAAS Capital Management sold 16,465 VYNE Therapeutics shares in Q3 2020, an estimated $2.05M.
  • CAAS Capital Management first reported a position in VYNE Therapeutics in Q2 2020 and held it in 1 quarter.
  • CAAS Capital Management's VYNE Therapeutics position peaked at $2.05M in Q2 2020.
  • 105 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2020.

Based on CAAS Capital Management's 13F filing for Q3 2020, filed 9 Nov 2020.